Sec Form 3 Filing - Sjuts Dustin S @ Revance Therapeutics, Inc. - 2019-12-01

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Sjuts Dustin S 2. Issuer Name and Ticker or Trading Symbol Revance Therapeutics, Inc. [ RVNC] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Commercial Officer (Last) (First) (Middle) C/O REVANCE THERAPEUTICS, INC, 7555 GATEWAY BLVD 3. Date of Earliest Transaction (MM/DD/YY) 12/01/2019 (Street) NEWARK, CA94560 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 4,568 ( 1 ) ( 2 ) D Common Stock 5,000 ( 3 ) D Common Stock 2,500 ( 4 ) D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Employee Stock Option (Right to Buy) $ 29.85 ( 5 ) 02/29/2028 Common Stock 28,000 D Employee Stock Option (Right to Buy) $ 24.96 ( 6 ) 11/04/2028 Common Stock 30,000 D Employee Stock Option (Right to Buy) $ 17.23 ( 7 ) 01/23/2029 Common Stock 10,000 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Sjuts Dustin S C/O REVANCE THERAPEUTICS, INC 7555 GATEWAY BLVD NEWARK, CA94560 Chief Commercial Officer Signatures /s/ Caryn McDowell, Attorney-in-Fact 12/10/2019 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The shares subject to the Restricted Stock award ("RSA") shall vest in four (4) equal annual installments beginning from April 15, 2018, subject to Mr. Sjuts' Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan (the "Plan")) on each vesting date. ( 2 )Excludes 432 shares withheld by and surrendered to the Issuer on April 15, 2019 to satisfy tax withholding obligations that arose in connection with vesting of the RSA for 5,000 shares. ( 3 )The shares subject to the RSA shall vest in three (3) equal annual installments beginning from December 15, 2018, subject to Reporting Person's Continuous Service (as defined in the Plan) on each vesting date. ( 4 )The shares subject to the RSA shall vest in three (3) equal annual installments beginning from February 15, 2019, subject to Reporting Person's Continuous Service on each vesting date. ( 5 )The Option shall vest as follows: 25% of the shares subject to the Option shall vest on the first anniversary of the vesting commencement date of March 1, 2018, and 1/48th vesting each month thereafter subject to Reporting Person's Continuous Service as of each such vesting date. ( 6 )The Option shall vest as follows: 1/48th of the total number of shares subject to the Option shall vest in 48 equal monthly installments over 4 years beginning from November 5,2018, subject to Reporting Person's Continuous Service as of each such vesting date. ( 7 )The Option shall vest as follows: 1/48th of the total number of shares subject to the Option shall vest in 48 equal monthly installments over 4 years beginning from January 24, 2019, subject to Reporting Person's Continuous Service as of each such vesting date.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.